{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=44&sponsor=Pfizer",
    "query": {
      "sponsor": "Pfizer",
      "page": 44
    },
    "page_size": 10
  },
  "pagination": {
    "page": 44,
    "page_size": 10,
    "total_count": 3279,
    "total_pages": 328,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=45&sponsor=Pfizer&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=43&sponsor=Pfizer&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T06:58:17.106Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04297384",
      "title": "Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Breast Carcinoma",
        "Metastatic Breast Carcinoma",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Recurrent Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Informational Intervention",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 174,
      "start_date": "2019-02-06",
      "completion_date": "2022-08-30",
      "has_results": false,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04297384"
    },
    {
      "nct_id": "NCT00525733",
      "title": "Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "darunavir 800 mg",
          "type": "DRUG"
        },
        {
          "name": "FTC 200 mg/TDF 300mg",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc",
          "type": "DRUG"
        },
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rockefeller University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2007-10",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-03-09",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00525733"
    },
    {
      "nct_id": "NCT00574834",
      "title": "Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Ramipril",
          "type": "DRUG"
        },
        {
          "name": "HCTZ-hydrochlorothiazide",
          "type": "DRUG"
        },
        {
          "name": "Ramipril+HCTZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "20 Years to 65 Years"
      },
      "enrollment_count": 17,
      "start_date": "2007-03",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2019-09-12",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574834"
    },
    {
      "nct_id": "NCT00952198",
      "title": "A Safety Study of ARRY-403 in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "ARRY-403, glucokinase activator; oral",
          "type": "DRUG"
        },
        {
          "name": "Placebo; oral",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 128,
      "start_date": "2009-08",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 2,
      "location_summary": "Chula Vista, California • San Antonio, Texas",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00952198"
    },
    {
      "nct_id": "NCT01396187",
      "title": "Safety and Tolerability of Ascending Intravenous Doses of PF-05231023 In Adult Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "PF-05231023",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2011-07",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2015-01-12",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 5,
      "location_summary": "Chula Vista, California • Miami, Florida • South Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01396187"
    },
    {
      "nct_id": "NCT02475733",
      "title": "Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Complicated Intra-abdominal Infections"
      ],
      "interventions": [
        {
          "name": "Ceftazidime -avibactam",
          "type": "DRUG"
        },
        {
          "name": "Meropenem",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Months to 17 Years"
      },
      "enrollment_count": 83,
      "start_date": "2015-08-01",
      "completion_date": "2017-06-01",
      "has_results": true,
      "last_update_posted_date": "2018-08-09",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 4,
      "location_summary": "Orange, California • San Diego, California • Toledo, Ohio + 1 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475733"
    },
    {
      "nct_id": "NCT05096208",
      "title": "Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "RSV"
      ],
      "interventions": [
        {
          "name": "RSVpreF (Group 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSVpreF (Group 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSVpreF (Group 3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 1028,
      "start_date": "2021-10-21",
      "completion_date": "2022-04-04",
      "has_results": true,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 18,
      "location_summary": "Miami Lakes, Florida • Sunrise, Florida • Winter Park, Florida + 13 more",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096208"
    },
    {
      "nct_id": "NCT06199934",
      "title": "Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "SARS-CoV-2",
        "COVID-19 Vaccines"
      ],
      "interventions": [
        {
          "name": "Vaccination",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 19853610,
      "start_date": "2023-09-11",
      "completion_date": "2024-07-31",
      "has_results": true,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06199934"
    },
    {
      "nct_id": "NCT03031938",
      "title": "Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis",
        "Cancer Pain",
        "Recurrent Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Investigational medical product (IMP) administered in parent study",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "2 Months",
        "sex": "ALL",
        "summary": "0 Years to 2 Months"
      },
      "enrollment_count": 4,
      "start_date": "2017-11-03",
      "completion_date": "2020-06-04",
      "has_results": true,
      "last_update_posted_date": "2021-06-25",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sarasota, Florida • Tampa, Florida + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03031938"
    },
    {
      "nct_id": "NCT04903093",
      "title": "A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Abrocitinib tablet",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F1",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F2",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F3",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F4",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F5",
          "type": "DRUG"
        },
        {
          "name": "Abrocitinib Suspension F6",
          "type": "DRUG"
        },
        {
          "name": "Famotidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2021-06-04",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2024-11-14",
      "last_synced_at": "2026-10-31T06:58:17.106Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04903093"
    }
  ]
}